Publication Name	World Journal of Ophthalmology
Manuscript ID	17182
Country	United States

Received	2015-02-22 09:39
Peer-Review Started	2015-02-22 16:53
To Make the First Decision	2015-06-03 14:39
Return for Revision	2015-06-04 16:21
Revised	2015-06-23 00:00
Second Decision	2015-08-07 17:47
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-08-14 16:19
Articles in Press	2015-08-14 16:20
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-10-30 20:38
Publish the Manuscript Online	2015-11-13 15:33

ISSN	2218-6239 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Ophthalmology
Manuscript Type	Editorial
Article Title	Curing diabetic retinopathy: Is a strategy emerging?
Manuscript Source	Invited Manuscript
All Author List	Michael W Stewart
Funding Agency and Grant Number
Corresponding Author	Michael W Stewart, MD, Department of Ophthalmology, Mayo Clinic Florida, 4500 San Pablo Rd., Jacksonville, FL 32224, United States. stewart.michael@mayo.edu
Key Words	Diabetic macular edema; Ranibizumab; Aflibercept; Diabetic retinopathy; Vascular endothelial growth factor
Core Tip	Drugs that prevent the binding of vascular endothelial growth factor (VEGF) produce greater gains in best corrected visual than can be achieved with laser photocoagulation. The recently completed pivotal phase Ⅲ trials showed that regular injections of ranibizumab and aflibercept over 2 years also improved the severity of diabetic retinopathy (DR). Both drugs have now been approved for the treatment of DR in patients with diabetic macular edema (DME) thereby allowing physicians to consider VEGF inhibition to improve DR in patients with vision threatening DME.
Publish Date	2015-11-13 15:33
Citation	Stewart MW. Curing diabetic retinopathy: Is a strategy emerging? World J Ophthalmol 2015; 5(4): 142-144
URL	http://www.wjgnet.com/2218-6239/full/v5/i4/142.htm
DOI	http://dx.doi.org/10.5318/wjo.v5.i4.142

Full Article (PDF)	WJO-5-142.pdf
Full Article (Word)	WJO-5-142.doc
Manuscript File	17182-Review.docx
Answering Reviewers	17182-Answering reviewers.pdf
Audio Core Tip	17182-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	17182-Conflict-of-interest statement.pdf
Copyright License Agreement	17182-Copyright assignment.pdf
Peer-review Report	17182-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	17182-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	17182-Scientific misconduct check.pdf
Scientific Editor Work List	17182-Scientific editor work list.pdf